Results from the phase II MyPathway basket trial found that the HER2-targeted therapies pertuzumab and trastuzumab demonstrated durable activity in patients with a wide variety of tumors marked by HER2 amplification or overexpression, although responses were limited in those with … Read more
An independent data safety monitoring committee has not observed any safety issues with the phase 3 OVAL trial examining VB-111 in patients with platinum-resistant ovarian cancer, and as such, has recommended that the trial continue as planned.
By Courtney Marabella… Read more
Mayo Clinic researchers have developed a novel proton therapy technique to more specifically target cancer cells that resist other forms of treatment. The technique is called LEAP, an acronym for “biologically enhanced particle therapy.” The findings are published today in … Read more
Loss of ARID1A causes increased glutamine metabolism, which can be blocked pharmacologically to target ARID1A-mutant tumors.
Mutations that inactivate the ARID1A gene in ovarian cancer increase utilization of the glutamine amino acid making cancer cells dependent on glutamine metabolism, according … Read more
One patient had a complete response and the majority of patients achieved disease control at 12 weeks.
A phase 1 trial of an anti-folate receptor alpha (FolRα) human immunoglobulin G1 (IgG1) antibody for women with advanced ovarian cancer showed responses
KSQ Therapeutics is hoping to provide hope for ovarian and breast cancer patients that have developed a resistance to drugs and those who don’t respond at all by developing a drug that may be able to boost the effectiveness of … Read more
A recent finding by researchers at UBC’s faculty of medicine and the BC Cancer Research Institute (BCCRI) may offer a new treatment possibility for people diagnosed with a rare and aggressive form of ovarian cancer.
Small cell carcinoma of the … Read more
By Clayton Boldt, Ph.D
Advanced ovarian cancer most commonly metastasizes to the omentum, a layer of fatty tissue that wraps around and protects internal organs in the abdomen, but the reasons for this have not been well-understood. In a new … Read more
By Kristin Jenkins
The presence of a BRCA germ line mutation in patients with invasive epithelial ovarian cancer may confer a short-term survival advantage, but is not associated with a reduction in long-term mortality, researchers found.
A follow-up study comparing … Read more
By Andrea S. Blevins Primeau, PhD, MBA
There are many different types of agents used in the treatment of cancer, and they can generally be classified according to molecule type or their basic mechanism of action. Different cancer types have … Read more
A brand new type of cancer drug that acts as a ‘Trojan horse’ to get inside tumour cells has shown promise in patients with six different cancer types.
In patients with advanced, drug-resistant cancers, over a quarter with cervical and … Read more
Two new papers, published simultaneously in Nature Communications and led by researchers at McGill University, offer promise that a drug currently used to treat estrogen positive breast cancer may be effective in treating two different types of cancer, one rare … Read more
Researchers at The Institute of Cancer Research, London (ICR) have developed an artificial intelligence (AI) test that analyses the shape of tumour cells to identify patients with aggressive ovarian cancer.
The test is intended to enable tailored treatment based on … Read more
Medical science has made tremendous advances in “personalized medicine” — drugs that fight cancer and other diseases by boosting the immune system or targeting specific genetic traits.
Former U.S. President Jimmy Carter benefited from one of these
… Read moreWoman with ovarian cancer has incredible response to treatment selected based on her tumor molecular profile. This tumor testing is part of the tumor blueprint that Clearity provides.
By Pierre Valette
“It was definitely a ‘holy smokes’ moment,” recounts Justin … Read more
An analysis of the NRG Oncology clinical trial NRG-GY003 suggests that adding ipilimumab, a monoclonal antibody that targets the protein receptor CTLA-4, to a regimen with the checkpoint inhibitor nivolumab could improve the proportion with tumor response and progression-free survival … Read more
Combining a new targeted cancer drug with chemotherapy has shown promise in an early clinical trial, in patients with ovarian or lung cancer for whom all other treatments had failed.
The combination of targeted drug vistusertib along with paclitaxel chemotherapy … Read more
Proponents of precision medicine cite the growing numbers of successful precision cancer drugs. The examples of Herceptin (trastuzumab), Gleevec (imatinib mesylate), Xalkori (crizotinib), and Zelboraf (vemurafenib) come to mind. Skeptics, on the other hand, focus on the … Read more
New research has shown that ovarian cancer patients with a tumor mutation in the BRAF gene respond exceptionally well to treatment with targeted drugs, known as BRAF inhibitors.
BRAF inhibitors block the activity of mutated BRAF gene. They are currently … Read more
